Free Trial

HC Wainwright Issues Positive Forecast for Compugen Earnings

Compugen logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • HC Wainwright raised its FY2026 EPS forecast for Compugen to a loss of $0.31 per share from a projected loss of $0.35, while maintaining a Buy rating.
  • Compugen reported a quarterly loss of $0.06 per share, better than the $0.08 loss analysts expected; revenue of $3.82 million also exceeded the $1.28 million consensus estimate.
  • Analyst sentiment is broadly positive: MarketBeat reports a consensus Buy rating and a $5.00 price target, while the stock opened at $2.10.
  • MarketBeat previews top five stocks to own in December.

Compugen Ltd. (NASDAQ:CGEN - Free Report) - Equities researchers at HC Wainwright increased their FY2026 earnings per share (EPS) estimates for shares of Compugen in a research note issued to investors on Thursday, November 12th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will earn ($0.31) per share for the year, up from their prior forecast of ($0.35). HC Wainwright currently has a "Buy" rating on the stock. The consensus estimate for Compugen's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Compugen's Q4 2026 earnings at ($0.09) EPS, Q1 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.39) EPS.

Separately, Weiss Ratings restated a "hold (c-)" rating on shares of Compugen in a report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $5.00.

Get Our Latest Stock Report on Compugen

Compugen Stock Performance

NASDAQ CGEN opened at $2.10 on Monday. The stock has a 50-day simple moving average of $2.20 and a 200 day simple moving average of $2.29. The company has a market capitalization of $198.56 million, a PE ratio of 5.38 and a beta of 2.85. Compugen has a 12 month low of $1.43 and a 12 month high of $3.23.

Compugen (NASDAQ:CGEN - Get Free Report) last posted its quarterly earnings results on Monday, November 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. Compugen had a return on equity of 39.30% and a net margin of 47.90%. The business had revenue of $3.82 million for the quarter, compared to analyst estimates of $1.28 million. During the same period last year, the company earned ($0.07) EPS.

Institutional Investors Weigh In On Compugen

Several large investors have recently bought and sold shares of CGEN. Tocqueville Asset Management L.P. bought a new position in Compugen during the third quarter worth about $125,000. Joel Isaacson & Co. LLC grew its stake in Compugen by 291.7% in the third quarter. Joel Isaacson & Co. LLC now owns 47,000 shares of the biotechnology company's stock valued at $112,000 after acquiring an additional 35,000 shares during the period. WINTON GROUP Ltd increased its holdings in shares of Compugen by 26.0% in the second quarter. WINTON GROUP Ltd now owns 197,110 shares of the biotechnology company's stock worth $422,000 after acquiring an additional 40,614 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Compugen in the second quarter worth about $110,000. Finally, Glenmede Trust Co. NA increased its holdings in shares of Compugen by 187.5% in the first quarter. Glenmede Trust Co. NA now owns 34,500 shares of the biotechnology company's stock worth $73,000 after acquiring an additional 22,500 shares in the last quarter. Institutional investors own 12.22% of the company's stock.

Compugen Company Profile

(Get Free Report)

Compugen Ltd. is an Israel-based clinical-stage biotechnology company focused on discovering and developing cancer immunotherapies. Founded in 1993, the company uses computational biology and related technologies to identify potential drug targets and develop antibody-based treatments. Its research centers on immune checkpoint pathways that can affect how the body's immune system recognizes and attacks tumors. Compugen's programs have included antibody candidates targeting PVRIG and TIGIT, among other potential therapies.

Read More

Earnings History and Estimates for Compugen (NASDAQ:CGEN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Compugen Right Now?

Before you consider Compugen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compugen wasn't on the list.

While Compugen currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines